Pelacarsen long-term extension study
Treatments studied
Part of Heart & circulation clinical trials.
This trial is for people who have already finished taking pelacarsen in a previous study. It offers continued access to the drug and checks long-term safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed a previous pelacarsen study and were still taking the drug at the end.
- You didn't stop taking the study drug early because of side effects or other rules.
- You don't have any medical condition that the study doctor thinks would make it unsafe for you to participate.
- You aren't currently taking another experimental drug or device.
- You don't have a known allergy to pelacarsen that would make it unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
This study follows patients who completed an earlier pelacarsen trial to check if the treatment remains safe and well-tolerated over time. Pelacarsen is an experimental medicine being tested for heart and cholesterol health.
This program provides access to pelacarsen (TQJ230) for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer potential benefit when standard therapies are not suitable.
This study tests whether pelacarsen, an experimental medicine, can safely lower Lp(a)—a type of cholesterol linked to heart disease—in people who recently had a heart attack. The goal is to see if lowering Lp(a) can help prevent future heart problems.
This is a follow-up study for people who are already taking the drug pelabresib in another trial and are doing well on it. It allows you to continue receiving pelabresib and monitors your health over a longer period.
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.